Dilip Kumar Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dilip Kumar Patel has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Prasanta Purohit
Multi-Disciplinary Research Unit (MRU), M.K.C.G. Medical College, Berhampur, India
5 shared publications Siris Patel
Sickle Cell Clinic and Molecular Biology Laboratory Veer Surendra Sai Medical College Burla Sambalpur Odisha India
5 shared publications- Ranjeet Singh Mashon
Indian Council of Medical Research (ICMR), Veer Surendra Sai Medical College, Burla, Orissa, India
3 shared publications - Satyabrata Meher
Odisha Sickle Cell Project (NHM), Veer Surendra Sai Institute of Medical Science and Research (VIMSAR), Burla, Sambalpur, Odisha, 768017, India; Multi-disciplinary Research Unit (MRU), (ICMR-DHR, MoHFW, GoI), Veer Surendra Sai Institute of Medical Science and Research (VIMSAR), Burla, Sambalpur, Odisha, 768017, India
3 shared publications Bhabani Shankar Das
Indian Council of Medical Research (ICMR), Veer Surendra Sai Medical College, Burla, Orissa, India
2 shared publicationsK. Das
Odisha Sickle Cell Project Veer Surendra Sai Medical College Burla Sambalpur Odisha India
2 shared publications
Latest Publications
- 24 December 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (6) , 1017-1023
Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1‐5(G→C) mutation
Background Despite compelling evidence that hydroxyurea is safe and effective in sickle cell disease, it is prescribed sparingly due to several barriers like knowledge gaps in certain genotypes, apprehension about its safety and toxicity, and limited resources. We undertook this study to find out the efficacy and safety of HU in patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Procedure We registered 318 patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Of these, 203 were enrolled for hydroxyurea treatment at a low and fixed dose of 10 mg/kg/day. One hundred four patients (Group-I: 37 children and Group-II: 67 adults) with ≥2 years of hydroxyurea treatment were studied. Results The rate of vaso-occlusive crises, requirement of blood transfusion and rate of hospitalization reduced from 3 to 0.5, 1 to 0 and 1 to 0 in Group-I and 3 to 0, 1 to 0 and 0.5 to 0 in Group-II respectively after HU therapy (P < 0.0001). %HbF level, hemoglobin, MCV and MCH increased significantly, whereas HbS, WBC, platelet count, serum-bilirubin and LDH levels decreased significantly after HU therapy. It has been observed that along with fairly subtle hematological changes following HU therapy, there was a substantial clinical improvement occurred in these patients. Transient myelotoxicity was observed in 4.8%. There was minimal gonadal toxicity without affecting reproductive function. Conclusion In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ+-thalassemia in resource poor setting. Pediatr Blood Cancer 2015;62:1017–1023.
- 24 December 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (6) , 1017-1023
Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1‐5(G→C) mutation
Background Despite compelling evidence that hydroxyurea is safe and effective in sickle cell disease, it is prescribed sparingly due to several barriers like knowledge gaps in certain genotypes, apprehension about its safety and toxicity, and limited resources. We undertook this study to find out the efficacy and safety of HU in patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Procedure We registered 318 patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Of these, 203 were enrolled for hydroxyurea treatment at a low and fixed dose of 10 mg/kg/day. One hundred four patients (Group-I: 37 children and Group-II: 67 adults) with ≥2 years of hydroxyurea treatment were studied. Results The rate of vaso-occlusive crises, requirement of blood transfusion and rate of hospitalization reduced from 3 to 0.5, 1 to 0 and 1 to 0 in Group-I and 3 to 0, 1 to 0 and 0.5 to 0 in Group-II respectively after HU therapy (P < 0.0001). %HbF level, hemoglobin, MCV and MCH increased significantly, whereas HbS, WBC, platelet count, serum-bilirubin and LDH levels decreased significantly after HU therapy. It has been observed that along with fairly subtle hematological changes following HU therapy, there was a substantial clinical improvement occurred in these patients. Transient myelotoxicity was observed in 4.8%. There was minimal gonadal toxicity without affecting reproductive function. Conclusion In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ+-thalassemia in resource poor setting. Pediatr Blood Cancer 2015;62:1017–1023.
- Open Access
- 11 March 2014
- Published by Wiley in ISRN Hematology
- Vol. 2014, 1-6
Prevalence of Deletional Alpha Thalassemia and Sickle Gene in a Tribal Dominated Malaria Endemic Area of Eastern India
Inherited hemoglobin disorders like alpha thalassemia and sickle gene are common in the Indian subcontinent. These disorders in the heterozygous state act as malaria resistance genes and influence the susceptibility toPlasmodium falciparummalaria. There is inadequate knowledge about the epidemiology of these malaria resistance genes in the tribal dominated malaria endemic region of the state of Odisha in eastern India. A cross sectional prevalence study was undertaken in 594 subjects in five tribal populations in this region, namely, Sahara (42.4%), Kutia Kandha (30.0%), Kuda (15.8%), Gond (9.8%), and Oraon (2.0%). Sickling test, Hb electrophoresis, HPLC, and molecular studies were undertaken to diagnose the prevalence of sickle allele,β-thalassemia allele, and deletional alpha thalassemia. Sickle andβthalassemia alleles were found in 13.1% and 3.4% of subjects, respectively. Sickle allele was found both in heterozygous (10.1%) and homozygous state (3.03%). The prevalence of alpha thalassemia was 50.84% with an allelic frequency of 0.37. Bothα−3.7andα−4.2alpha thalassemia were detected with an allele frequency of 0.33 and 0.04, respectively. The high prevalence of alpha thalassemia and sickle gene in this population is probably due to selection pressure of endemic malaria in this part of India.
- 11 March 2014
- Published by Wiley in ISRN Hematology
- Vol. 2014, 1-6
Open AccessPrevalence of Deletional Alpha Thalassemia and Sickle Gene in a Tribal Dominated Malaria Endemic Area of Eastern India
Inherited hemoglobin disorders like alpha thalassemia and sickle gene are common in the Indian subcontinent. These disorders in the heterozygous state act as malaria resistance genes and influence the susceptibility toPlasmodium falciparummalaria. There is inadequate knowledge about the epidemiology of these malaria resistance genes in the tribal dominated malaria endemic region of the state of Odisha in eastern India. A cross sectional prevalence study was undertaken in 594 subjects in five tribal populations in this region, namely, Sahara (42.4%), Kutia Kandha (30.0%), Kuda (15.8%), Gond (9.8%), and Oraon (2.0%). Sickling test, Hb electrophoresis, HPLC, and molecular studies were undertaken to diagnose the prevalence of sickle allele,β-thalassemia allele, and deletional alpha thalassemia. Sickle andβthalassemia alleles were found in 13.1% and 3.4% of subjects, respectively. Sickle allele was found both in heterozygous (10.1%) and homozygous state (3.03%). The prevalence of alpha thalassemia was 50.84% with an allelic frequency of 0.37. Bothα−3.7andα−4.2alpha thalassemia were detected with an allele frequency of 0.33 and 0.04, respectively. The high prevalence of alpha thalassemia and sickle gene in this population is probably due to selection pressure of endemic malaria in this part of India.
- 24 February 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (8) , 1341-1346
The effect of hydroxyurea on compound heterozygotes for sickle cell‐hemoglobin D‐Punjab—A single centre experience in eastern India
Background: Although hydroxyurea is the only effective agent for the treatment of sickle cell disease, published experience with this drug is limited to treatment of homozygous sickle cell anemia and HbS/β thalassemia. The role of hydroxyurea in the treatment of patients with HbSD‐Punjab, a rare hemoglobinopathy with phenotypic expression similar to that of sickle cell anemia is unknown.Procedure: Over a period of 10 years, we followed 42 patients with HbSD‐Punjab, of which 20 presented with severe clinical manifestations (≥3 episodes of VOC and/or ≥2 units of blood transfusion in the previous 12 months). These 20 patients were enrolled for treatment with hydroxyurea at a dose of 10 mg/kg/day and followed prospectively for a period of 24 months.Results: The frequency of VOC decreased significantly and none of them required blood transfusion while receiving hydroxyurea. The HbF, total hemoglobin, MCV, MCH, and MCHC levels increased significantly, whereas HbS, WBC, platelet count, total serum bilirubin, and LDH levels decreased significantly in all the patients. No short‐term drug toxicity was observed.Conclusion: This study describes the use of hydroxyurea therapy in patients with HbSD‐Punjab. Low dose hydroxyurea (10 mg/kg/day) was found to be effective in reducing the clinical severity in patients with HbSD‐Punjab without any short‐term toxicity. In view of easy affordability amongst poor patients, widespread acceptability by patients and doctors, the need of infrequent monitoring and its potential effectiveness, low dose hydroxyurea is suitable for treatment of patients with HbSD‐Punjab. Pediatr Blood Cancer 2014; 61:1341–1346.
- 24 February 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (8) , 1341-1346
The effect of hydroxyurea on compound heterozygotes for sickle cell‐hemoglobin D‐Punjab—A single centre experience in eastern India
Background: Although hydroxyurea is the only effective agent for the treatment of sickle cell disease, published experience with this drug is limited to treatment of homozygous sickle cell anemia and HbS/β thalassemia. The role of hydroxyurea in the treatment of patients with HbSD‐Punjab, a rare hemoglobinopathy with phenotypic expression similar to that of sickle cell anemia is unknown.Procedure: Over a period of 10 years, we followed 42 patients with HbSD‐Punjab, of which 20 presented with severe clinical manifestations (≥3 episodes of VOC and/or ≥2 units of blood transfusion in the previous 12 months). These 20 patients were enrolled for treatment with hydroxyurea at a dose of 10 mg/kg/day and followed prospectively for a period of 24 months.Results: The frequency of VOC decreased significantly and none of them required blood transfusion while receiving hydroxyurea. The HbF, total hemoglobin, MCV, MCH, and MCHC levels increased significantly, whereas HbS, WBC, platelet count, total serum bilirubin, and LDH levels decreased significantly in all the patients. No short‐term drug toxicity was observed.Conclusion: This study describes the use of hydroxyurea therapy in patients with HbSD‐Punjab. Low dose hydroxyurea (10 mg/kg/day) was found to be effective in reducing the clinical severity in patients with HbSD‐Punjab without any short‐term toxicity. In view of easy affordability amongst poor patients, widespread acceptability by patients and doctors, the need of infrequent monitoring and its potential effectiveness, low dose hydroxyurea is suitable for treatment of patients with HbSD‐Punjab. Pediatr Blood Cancer 2014; 61:1341–1346.
- 19 November 2013
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (4) , 444-450
Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD‐Punjab
Summary: Introduction: HbSD‐Punjab (HbSD) is a less common form of sickle cell disease (SCD) and discrimination between HbSD and HbSS is not possible on alkaline electrophoresis because the two variants overlap in the compound heterozygous state. There are only a few publications consisting mostly of case reports. Thus, the phenotypic expression of HbSD and its modifiers has not been studied.Methods: We studied the phenotypic expression of 42 cases of HbSD (the largest number of subjects ever included in this kind of study) and compared them with 84 HbSS cases matched for age, sex, and caste. Further, we evaluated the influence of HbF concentration and alpha thalassemia on the phenotypic expressions of HbSD, namely the frequency of VOC and degree of hemolysis.Results: The frequencies of VOC were similar in both the groups. The markers of hemolysis such as total bilirubin, unconjugated bilirubin, and LDH were higher where as HbF concentration was significantly low in HbSD. There was a negative correlation between HbF concentration and risk of VOC in the HbSD. The total hemoglobin level and hematocrit were significantly high, and the MCV and MCH were significantly low in HbSD with alpha thalassemia. Alpha thalassemia had no influence on the frequency of VOC and severity of hemolysis in HbSD.Conclusion: HbF reduced the frequency of VOC but had no influence on the hemolytic markers in HbSD. HbSD with alpha thalassemia was associated with hypohromic and microcytic features of red blood cells.
- 19 November 2013
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (4) , 444-450
Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD‐Punjab
Summary: Introduction: HbSD‐Punjab (HbSD) is a less common form of sickle cell disease (SCD) and discrimination between HbSD and HbSS is not possible on alkaline electrophoresis because the two variants overlap in the compound heterozygous state. There are only a few publications consisting mostly of case reports. Thus, the phenotypic expression of HbSD and its modifiers has not been studied.Methods: We studied the phenotypic expression of 42 cases of HbSD (the largest number of subjects ever included in this kind of study) and compared them with 84 HbSS cases matched for age, sex, and caste. Further, we evaluated the influence of HbF concentration and alpha thalassemia on the phenotypic expressions of HbSD, namely the frequency of VOC and degree of hemolysis.Results: The frequencies of VOC were similar in both the groups. The markers of hemolysis such as total bilirubin, unconjugated bilirubin, and LDH were higher where as HbF concentration was significantly low in HbSD. There was a negative correlation between HbF concentration and risk of VOC in the HbSD. The total hemoglobin level and hematocrit were significantly high, and the MCV and MCH were significantly low in HbSD with alpha thalassemia. Alpha thalassemia had no influence on the frequency of VOC and severity of hemolysis in HbSD.Conclusion: HbF reduced the frequency of VOC but had no influence on the hemolytic markers in HbSD. HbSD with alpha thalassemia was associated with hypohromic and microcytic features of red blood cells.
- 25 July 2013
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (1) , 71-76
Clinical and molecular characterization of Hb Hofu in eastern India
Summary: Introduction: Hb Hofu (HBB:c. 380T>A) is a rare inherited hemoglobin abnormality with few case reports in the world literature.Methods: Screening for the sickle cell gene mutation and other hemoglobinopathies was carried out using the sickle slide test, Hb electrophoresis, and HPLC under an ongoing central government project.Results: We detected twelve Hb Hofu heterozygotes and three sickle Hb Hofu compound heterozygotes. The heterozygotes were asymptomatic except for one individual who had chronic kidney disease and moderate anemia. Only one HbS‐Hofu case was symptomatic and presented with intermittent attacks of painful crisis. In the carrier state, the Hb Hofu eluted as a hump at the beginning of the HbA0 window. But in HbS‐Hofu cases, Hb Hofu eluted as a single peak in the HbA0 window, with the HbA2 levels being >4% consistently.Conclusion: HbS‐Hofu has a variable clinical presentation. The retention time of Hb Hofu on HPLC is very close to that of HbA0 and often elutes in the A0 window. Thus, there is every possibility of the HbS‐Hofu chromatogram to be misinterpreted as that of a sickle cell trait/transfused sickle cell‐beta‐thalassemia case. This is the first time where Hb Hofu has been detected by HPLC, which is the widely accepted screening technique for hemoglobinopathies around the world.
- 25 July 2013
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (1) , 71-76
Clinical and molecular characterization of Hb Hofu in eastern India
Summary: Introduction: Hb Hofu (HBB:c. 380T>A) is a rare inherited hemoglobin abnormality with few case reports in the world literature.Methods: Screening for the sickle cell gene mutation and other hemoglobinopathies was carried out using the sickle slide test, Hb electrophoresis, and HPLC under an ongoing central government project.Results: We detected twelve Hb Hofu heterozygotes and three sickle Hb Hofu compound heterozygotes. The heterozygotes were asymptomatic except for one individual who had chronic kidney disease and moderate anemia. Only one HbS‐Hofu case was symptomatic and presented with intermittent attacks of painful crisis. In the carrier state, the Hb Hofu eluted as a hump at the beginning of the HbA0 window. But in HbS‐Hofu cases, Hb Hofu eluted as a single peak in the HbA0 window, with the HbA2 levels being >4% consistently.Conclusion: HbS‐Hofu has a variable clinical presentation. The retention time of Hb Hofu on HPLC is very close to that of HbA0 and often elutes in the A0 window. Thus, there is every possibility of the HbS‐Hofu chromatogram to be misinterpreted as that of a sickle cell trait/transfused sickle cell‐beta‐thalassemia case. This is the first time where Hb Hofu has been detected by HPLC, which is the widely accepted screening technique for hemoglobinopathies around the world.
- 15 November 2010
- Published by Taylor & Francis in Hemoglobin
- Vol. 34 (6) , 604-609
Clinical and Molecular Characterization of βSandGγ(Aγδβ)0-Thalassemia in Eastern India
Fetal hemoglobin (Hb F) is the most studied modifier of sickle cell disease. Coinheritance of high Hb F determinants such as δβ-thalassemia (δβ-thal) and hereditary persistence of fetal hemoglobin (HPFH) can contribute to raised Hb F concentration in these patients. One hundred and seventy-six cases of sickle cell disease with high Hb F were screened for the presence of the Asian Indian deletion-inversion Gγ(Aγδβ)0-thal and HPFH-3 (Indian, 48.5 kb) disorders. Three cases from two unrelated families were found to have sickle cell disease and the (Aγδβ)0-thal genotype. Three other members had heterozygous Gγ(Aγδβ)0-thal. None had HPFH-3. Despite very high Hb F concentrations and linkage of the βS gene to Asian haplotypes, the compound heterozygotes had severe clinical presentation, possibly because of heterocellular distribution of Hb F. In conclusion, these high Hb F determinants are not common causes of high Hb F in Indian sickle cell disease patients.
- 15 November 2010
- Published by Taylor & Francis in Hemoglobin
- Vol. 34 (6) , 604-609
Clinical and Molecular Characterization of βSandGγ(Aγδβ)0-Thalassemia in Eastern India
Fetal hemoglobin (Hb F) is the most studied modifier of sickle cell disease. Coinheritance of high Hb F determinants such as δβ-thalassemia (δβ-thal) and hereditary persistence of fetal hemoglobin (HPFH) can contribute to raised Hb F concentration in these patients. One hundred and seventy-six cases of sickle cell disease with high Hb F were screened for the presence of the Asian Indian deletion-inversion Gγ(Aγδβ)0-thal and HPFH-3 (Indian, 48.5 kb) disorders. Three cases from two unrelated families were found to have sickle cell disease and the (Aγδβ)0-thal genotype. Three other members had heterozygous Gγ(Aγδβ)0-thal. None had HPFH-3. Despite very high Hb F concentrations and linkage of the βS gene to Asian haplotypes, the compound heterozygotes had severe clinical presentation, possibly because of heterocellular distribution of Hb F. In conclusion, these high Hb F determinants are not common causes of high Hb F in Indian sickle cell disease patients.
- 15 November 2010
- Published by Taylor & Francis in Hemoglobin
- Vol. 34 (6) , 530-537
β-Globin Gene Haplotypes Linked with the Hb D-Punjab [β121(GH4)Glu→Gln,GAA>CAA] Mutation in Eastern India
Hb D-Punjab [β121(GH4)Glu→Gln] is prevalent in the northern states of the Indian subcontinent. Due to inadequate data from Asian countries, the origin and spread of the Hb D-Punjab mutation are uncertain. In a study of sickle cell hemoglobinopathies, we detected the Hb D-Punjab mutation in 25 subjects from 11 unrelated Agharia families. Twelve cases were Hb S [β6(A3)Glu→Val]/Hb D-Punjab compound heterozygotes and 13 were Hb D trait carriers. In 76.0% of the cases, the βD gene was linked to haplotype I, whereas 24.0% had a novel haplotype. None of the haplotypes matched the βA haplotype of the local population. In view of the ancestral origin of the subjects and the high prevalence of the βD gene in the states of northern India, we suggest a North Indian origin for the βD mutation in our population. The finding of a novel haplotype in eastern India supports the hypothesis of a multicentric origin of this mutation.
- 15 November 2010
- Published by Taylor & Francis in Hemoglobin
- Vol. 34 (6) , 530-537
β-Globin Gene Haplotypes Linked with the Hb D-Punjab [β121(GH4)Glu→Gln,GAA>CAA] Mutation in Eastern India
Hb D-Punjab [β121(GH4)Glu→Gln] is prevalent in the northern states of the Indian subcontinent. Due to inadequate data from Asian countries, the origin and spread of the Hb D-Punjab mutation are uncertain. In a study of sickle cell hemoglobinopathies, we detected the Hb D-Punjab mutation in 25 subjects from 11 unrelated Agharia families. Twelve cases were Hb S [β6(A3)Glu→Val]/Hb D-Punjab compound heterozygotes and 13 were Hb D trait carriers. In 76.0% of the cases, the βD gene was linked to haplotype I, whereas 24.0% had a novel haplotype. None of the haplotypes matched the βA haplotype of the local population. In view of the ancestral origin of the subjects and the high prevalence of the βD gene in the states of northern India, we suggest a North Indian origin for the βD mutation in our population. The finding of a novel haplotype in eastern India supports the hypothesis of a multicentric origin of this mutation.
- 11 September 2009
- Published by Wiley in European Journal of Haematology
- Vol. 83 (4) , 383-384
Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis
- 11 September 2009
- Published by Wiley in European Journal of Haematology
- Vol. 83 (4) , 383-384
Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis